Webinars and Sponsored Roundtables — Register Now

Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.

Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.

Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Subspecialties

Interactive Product Guides

Marketplace Directory

c-MET biomarker, 9/15

Biocept launched its c-MET amplification detection test. This diagnostic assay, which uses a blood-based liquid biopsy, has the potential to help physicians identify patients who may be receptive to certain gastric and non-small cell lung cancer treatments.

Biocartis, Fast-track sign strategic collaboration, 9/15

Biocartis and Fast-track Diagnostics have entered into a strategic collaboration to develop a range of multiplex infectious disease tests to run on the Biocartis Idylla system. The two companies plan to collaborate on a new approach to infectious disease diagnostics, “syndromic multiplex testing,” which enables the identification of a broad range of disease pathogens in a single test.

Qiagen, Seegene partnership, 9/15

Qiagen announced a collaboration with Seegene in which Seegene will develop a menu of multiplex assay panels for Qiagen’s modular QIAsymphony RGQ MDx automation platform.

DiaSorin, Beckman Coulter sign distribution partnership, 9/15

DiaSorin and Beckman Coulter Diagnostics have signed a distribution partnership agreement for the commercialization in China of DiaSorin Hepatitis B, C, and HIV tests on DiaSorin’s Liaison XL LAS connected to Beckman Coulter’s Power Express and Power Processor automated sample processing systems.

CLSI Excellence Awards, 9/15

CLSI’s Excellence Awards are bestowed on volunteers who are dedicated and committed to the organization’s mission and who significantly contribute their services to the development, implementation, and promotion of consensus standards. The winners were nominated by their peers and then selected by the CLSI Awards Committee and announced in July.

Quality management system certification, 9/15

Biomedical Polymers has received ISO 13485:2003 certification for its Quality Management System for the manufacture of Medical Devices. In order to meet these requirements for certification, BMP upgraded its quality management system to assist in achieving increased efficiencies, higher performance, and reduced operational costs.

CE mark for software, 9/15

Ariosa Diagnostics’ proprietary Forte software received the CE mark—a significant achievement toward the continued expansion of the Harmony Prenatal Test in Europe and worldwide, according to a company statement.

Solid tumor mutation mix, 9/15

SeraCare Life Sciences’ new precision medicine business unit has launched its first product, the Seraseq Solid Tumor Mutation Mix—I (AF20), a biosynthetic reference material designed to evaluate the performance of next-generation-sequencing–based tumor profiling assays.

Core biopsy system, 9/15

Medtronic offers the GenCut core biopsy system, a lung tissue biopsy tool for use with the SuperDimension navigation system, which enables a minimally invasive approach to accessing difficult-to-reach areas of the lung.

Next-generation cell culture line, 9/15

Sarstedt introduced its next generation of cell culture flasks, dishes, and plates redesigned for “superior growth, economic handling, and traceability,” according to a company statement. All items are imprinted with lot number and expiration date and are individually color-coded for one of three culture surfaces. Flasks and dishes are packaged in resealable zip bags, and individual plate packaging has been optimized for easy opening and compact storage.